Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 26
- Jun 29, 2024
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
Kasi, et. al.
Filter by
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
AGEN1884, an IgG1 anti-CTLA-4 Antibody, Combines Effectively with PD-1 Blockade in Primary Human T Cell Assays and in a Non-human Primate Pharmacodynamic (PD) Model.
Drouin, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 2
- Jun 6, 2017
Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies.
Wilky, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 12, 2017
Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates.
Gombos, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN1884, an Anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade.
Wilky, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Zalifrelimab (CTLA-4 Antagonist)
PLOS
Apr 4, 2018
Toxicological and Pharmacological Assessment of AGEN1884, a Novel Human IgG1 anti-CTLA-4 Antibody.
Gombos, et al.
Zalifrelimab (CTLA-4 Antagonist)
Journal for ImmunoTherapy of Cancer
Aug 8, 2019
Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution.
Florou, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials.
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822).
Perez, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer.
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.